Nasal Polyps Treatment Market to Surpass US$ 5,088.90 Million by 2030 - Coherent Market Insights

News provided by

Aug 29, 2022, 14:45 ET

SEATTLE, Aug. 29, 2022 /PRNewswire/ -- According to Coherent Market Insights, the global nasal polyps treatment market is estimated to be valued at US$ 2,992.21 Million in 2022 and is expected to exhibit a CAGR of 6.9% during the forecast period (2022-2030).

Key Trends and Analysis of the Global Nasal Polyps Treatment Market:

Key trends in market include increasing product launches, increasing prevalence of sinusitis, regulatory approvals for new drugs, increasing drug trails etc.

Market players are engaged in Drug Trials for testing new drugs for the treatment of nasal polyps, which is expected to drive growth of the global nasal polyps treatment market. For instance, on September 5, 2021, Amgen, a biopharmaceutical company, had announced the completion of Phase III trials for Tezepelumab. Phase 3 trails data showed that tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps. The examination showed that tezepelumab's had ability to reduce the symptoms of nasal polyps, reduce exacerbations and improve lung function in comorbid population who are typically more prone to asthma attacks.

Large of people getting diagnose for inusitis is expected to drive growth of the global nasal polyps treatment market, over the forecast period. For instance, according to Sinus & Allergy Wellness Center of North Scottsdale, as of 2020-2019 – Sinusitis Facts and Data, about 30 million adults get impacted by sinusitis annually in the U.S. and about 11.6% of adults get diagnosed for sinusitis. Increasing diagnosis for sinusitis would rise the treatment demand through which it is expected to drive growth of the global nasal polyps treatment market.

Request for Sample Copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/2775

Market Players are getting approval for new drugs from regulatory bodies, which is expected to drive growth of the global nasal polyps treatment market, over the forecast period. For instance, in November 2017, AstraZeneca, a pharmaceutical and biotechnology company got approval from U.S. Food and Drug Administration for its drug Fasenra (benralizumab). The people above age 12 suffering from severe asthma, fasenra is an additional preservation treatment for them. Nasal polyps develop from long-term inflammation and swelling in sinuses. People with respiratory diseases, such as asthma and chronic rhinosinusitis, have a larger chance of having nasal polyps. Nasal Polyps are related to disorders such as asthma. Increasing regulatory approvals for new drugs is expected to give opportunity for growth of the nasal polyps treatment market.

Key Market Takeaways:

Increasing population affected with chronic rhinosinusitis disorder is expected to drive growth of the global nasal polyps treatment market, over the forecast period. For instance, according to data published in July 2020, by National Center for Biotechnology Information, in Europe, China and in U.S.about 10.9% , 13% and 12.3% people are affected with chronic rhinosinusitis, respectively. Nasal polyps are inflammatory extensions of paranasal sinus mucosa produced by long-lasting mucosal swelling and are present in 20% of patients with chronic rhinosinusitis

Among regions, North America is expected to hold a dominant position in the global nasal polyps treatment market over the forecast period, owing to getting approvals by federal agency for the reimbursement of money used for treatment of nasal polyps. For instance in June 2020, Intersect ENT, a medical device company, got approved by Centers for Medicare and Medicaid Services to SINUVA Sinus Implant for reimbursement, with New C–Code. New C Code for SINUVA will make simpler the reimbursement process for ENT physicians and their practices, as well as provide Medicare patients easier access to this novel drug eluting sinus implant

Key players operating in the global nasal polyps treatment market include Regeneron Pharmaceuticals, Inc., Hoffmann-La Roche Ag, Fougera Pharmaceuticals Inc., Novartis International Ag, Sanofi S.A., GlaxoSmithKline Plc, Intersect Ent, Dohme Corp, Merck & Co., Inc., Sanofi S.A., Norton Waterford Ltd, Astrazeneca Plc, Taro Pharmaceuticals Industries Ltd., Teva Pharmaceutical Industries Limited, and OptiNose Inc.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/2775

Detailed Segmentation:

Global Nasal Polyps Treatment Market, By Drug Class:

Corticosteroids

Nasal corticosteroids

Fluticasone
Budesonide
Mometasone
Triamcinolone
Others - Beclomethasone, Ciclesonide, etc.

Oral/Injectable Corticosteroids

Prednisone
Combination

Antibiotics
Antihistamines
Interleukin Inhibitors

Dupilumab

Others (IL 10, IL 25 etc.)
Monoclonal Antibodies

Mepolizumab
Omalizumab
Others

Others (Aspirin, anticholinergic agent and etc.)

Global Nasal Polyps Treatment Market, By Route of Administration:

Nasal
Oral
Parenteral

Global Nasal Polyps Treatment Market, By Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Nasal Polyps Treatment Market, By Region:

North America

By Country:

U.S.
Canada

Europe

By Country:

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

By Country:

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific

Latin America

By Country:

Brazil
Mexico
Argentina
Rest of Latin America

Middle East & Africa

By Country:

GCC Countries
Israel
South Africa
Rest of Middle East & Africa

Buy this Complete Report Now @ https://www.coherentmarketinsights.com/insight/buy-now/2775

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.

Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: [email protected]
Website: https://www.coherentmarketinsights.com
Follow Us: LinkedIn | Twitter